regimens, potential drug interactions with immunosuppressant and nonimmunosuppressant medications, viral relapse, viral resistance, and infection with multiple viral strains. 5, 6 Although clinical trials are under way in the United States and preliminary findings are reassuring, there is consensus that larger clinical experience and patient follow-up are needed before the use of HCV NATpositive donor kidneys in HCV-negative recipients is routinely adopted into clinical transplant practice. 7, 8 A significant challenge is the need for rapid posttransplant treatment with DAAs. This necessitates a commitment from health insurers to provide coverage for DAAs prior to transplantation (typical market cost of DAA regimens is $45 000 to $100 000 Canadian dollars). 9 DAAs are not approved nor routinely covered by insurance providers to support the use of HCV-positive donor organs for transplantation in HCVnegative recipients, and information about the cost effectiveness of using DAA for this indication may be useful in helping advance clinical trials to better understand this strategy.
In our review of the literature, only 1 study has examined the cost of using HCV NA-positive kidneys for transplantation. 10 This study projected that there would be cost-savings if there was a >4-year reduction in the waiting time for transplantation by using a HCV NAT-positive kidney. 10 This study did not consider the quality of life of patients, survival, or the potential need for a second course of DAA treatment. The current study is motivated by the need to inform researchers, payers, and decision makers regarding the use of HCV NAT-positive donor kidneys in HCV-negative wait-list candidates. This cost-effectiveness analysis examines the purposeful use of HCV NAT-positive donor kidneys for transplantation in previously uninfected waitlist candidates followed by treatment with DAAs compared to the alternative of remaining on the kidney transplant waitlist from a HCV NAT-negative kidney transplant. 
| MATERIAL SANDME THODS

| Studydesign
| Healthstatesandoutcomes
Possible patient health states in the models include dialysis dependent, alive with a functioning kidney transplant, and de- In the primary models, all patients receiving a kidney from a HCV NAT-positive donor would receive DAA therapy. Based on the treatment regimens used in prior studies, a 12-week course of elbasvir/ grazoprevir was used as the first course of therapy in the model. 7, 8 It was assumed that up to 4% of patients would require further therapy with an alternate DAA treatment regimen based on published sustained viral response rates. [13] [14] [15] Given that the second DAA treatment regimen may vary depending on viral genotype and prescriber preference, the cost of a second course of therapy was set as equivalent to the cost of the first DAA drug regimen. 
| Cost,utility,andprobabilityestimates
The model was informed by previous estimates of cost and utility for dialysis and transplant ( Table 1 ). The cost and utility estimates were derived from the published literature with costs adjusted for inflation to 2017 Canadian dollars. Health-care payers have negotiated a lower cost for DAAs; however, the negotiated cost of these drugs is frequently confidential; therefore, market value was used in this analysis and a lower negotiated price was explored in a sensitivity analysis. 9 The cost of specialist consultation and follow-up included a pretransplant assessment of cirrhosis with transient elastography (required to rule out pre-existing cirrhosis), HCV viral monitoring posttransplantation, and HCV drug susceptibility testing, derived from locally obtained fee lists and previously published estimates. [16] [17] [18] The cost of a year of dialysis therapy was derived from a Canadian study of the cost of peritoneal, in-center hemodialysis, and home hemodialysis. 19 A final cost estimate for a year of dialysis therapy assumed a ratio of in-center hemodialysis to home hemodialysis to peritoneal dialysis of 0.75:0.05:0.20 as per the current prevalence of each therapy for treatment of kidney failure in Canada. 3 The cost of the first, TA B L E 1 Estimates used in the Markov model with their primary assigned value, plausible range used in subsequent sensitivity analyses, and references for these. Where possible, plausible ranges were derived from the literature. Otherwise, a 10% range was used as the plausible range second, and third year of care posttransplant was obtained from a previously published Canadian study. 20 The estimate of utility of a year of dialysis therapy and a year of transplant therapy was acquired from a systematic review that provides QALY estimates adjusted for the utility elicitation method for both dialysis and transplantation. Transition probabilities were derived from reported survival of waitlisted dialysis and transplant patients in Canada. 
| Modelassumptionsandlimitations
The study model assumes that the time to transplantation for wait- of patients would require a second course of treatment. 7, 8, [13] [14] [15] The model assumes that treatment with DAAs would not substantially impact patient quality of life and that after the HCV infection in a recipient was cured, the HCV infection would have no future impact on transplant or patient survival. The probability of death after return to dialysis in the models was equal to the probability of death in non-wait-listed dialysis patients.
| Sensitivityanalysis
To ensure robustness and external validity of the model outputs to health-care settings beyond Canada including the United States and other countries, we performed a variety of sensitivity analyses.
Uncertainty of the model parameters was determined using the plausible ranges in Table 1 . The plausible range for costs of 1 year of dialysis and transplant treatment was calculated, assuming a 10% range in the cost estimate. The plausible range for cost of DAAs was produced by assuming a potential 20% discount obtained by healthcare payers. Additionally, there is evidence to suggest that the risk of HCV transmission from donor to recipient may not be 100% in donors with low levels of viremia. 25 We therefore performed a sensitivity analysis exploring the possibility that some recipients may not be infected with HCV and therefore may not require DAA therapy. A 10% range was used for the transition probabilities where the probabilities varied with survival time. A 1-way sensitivity analysis was performed for all the parameters in Table 1 .
The long-term survival of previously uninfected patients who received a kidney transplant from a HCV NAT-positive donor is unknown. Several publications with short term but ongoing follow-up have documented that DAAs are safe in kidney transplant recipients and do not increase the risk of transplant failure. 13, 14 However, it is possible that DAAs may increase the risk of rejection because of drug interactions with immunosuppressant medications. Therefore, we performed a sensitivity analysis exploring the impact of 10% increase in overall relative risk of death-censored transplant failure.
We also conducted a probabilistic sensitivity analysis using probability distributions to replace the estimates for the parameters included in the model (ie, cost, utility, and survival probabilities). In this way, uncertainty in the model is represented by each of these distributions. We then analyzed the model repeatedly, with various combinations of parameter estimates that are drawn randomly from the probability distributions. In this case, we repeated the analysis 10 000 times. The results of these analyses are presented in costeffectiveness acceptability curves with thresholds of willingness-topay varying from $0 to $100 000 per QALY to include the range of internationally accepted willingness-to-pay thresholds.
| Budgetimpactassessment
Cumulative cost as a function of time was calculated using the cost of a HCV NAT-positive kidney to remaining on the waitlist for 1 additional year, the sensitivity analysis was robust, with the exception of the estimates of cost of DAAs and the annual cost of dialysis therapy (Figure 3) . When the cost of DAAs decreased to 80% of the market price, using a HCV NAT-positive kidney was cost-saving from the health-care payer perspective. The strategy of using a HCV NATpositive kidney in a HCV-negative recipient was cost neutral when the probability of disease transmission was 85%, and cost-saving when the probability for disease transmission was 75% (Figure 3 ).
| RE SULTS
Conversely, as the annual cost of dialysis therapy decreased, the incremental cost of using a HCV NAT-positive kidney compared to remaining on the wait-list for 1 further year was increased. We specifically evaluated a scenario where the overall relative risk of deathcensored transplant failure was increased by 10% with the use of DAAs. This scenario still dominated remaining on the waitlist for 2 or more years and when compared to remaining on the waitlist for 1 additional year, the ICER was still within a plausible willingness-topay threshold of $74 653/QALY.
We further explored the model comparing receipt of a HCV NATpositive kidney to remaining on the waitlist for 1 year with a probabilistic analysis. Using a HCV NAT-positive kidney was cost-effective using a willingness-to-pay threshold of $50 000 in 58% of the iterations. If the willingness-to-pay threshold was increased to $100 000/ QALY, using a HCV NAT-positive kidney was cost-effective in 93% of the iterations (Figure 4 ). 
| D ISCUSS I ON
The use of HCV NAT-positive kidneys followed by DAA treatment in Our analysis found that using kidneys from HCV NAT-positive donors in HCV NAT-negative recipients is likely to result in substantially more cost-savings than the previously published estimates. 10 To our knowledge, this is the first detailed cost-effectiveness analysis of this strategy. Although the results are promising, there are several assumptions informing this analysis and significant clinical questions that remain to be answered, namely, the long-term outcomes and patient acceptance of using HCV NAT-positive kidneys in HCV NAT-negative recipients.
In summary, we found that the use of HCV NAT-positive kidneys for transplantation in HCV-negative recipients followed by treatment with DAAs is likely to lead to improved patient outcomes, with significant cost-savings from both a health-care payer and societal 
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